Cargando…

Evolutionary characteristics of SARS-CoV-2 Omicron subvariants adapted to the host

Detalles Bibliográficos
Autores principales:	Tang, Haijun, Shao, Yun, Huang, Yi, Qiao, Shigang, An, Jianzhong, Yan, Ruhong, Zhao, Xin, Meng, Fang, Du, Xiaohong, Qin, F. Xiao-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204007/ https://www.ncbi.nlm.nih.gov/pubmed/37221221 http://dx.doi.org/10.1038/s41392-023-01449-w

Ejemplares similares

Omicron adopts a different strategy from Delta and other variants to adapt to host
por: Du, Xiaohong, et al.
Publicado: (2022)

Raman Fingerprints of SARS-CoV-2 Omicron Subvariants: Molecular Roots of Virological Characteristics and Evolutionary Directions
por: Pezzotti, Giuseppe, et al.
Publicado: (2023)

Clinical characteristics of liver injury in SARS-CoV-2 Omicron variant- and Omicron subvariant-infected patients
por: Deng, Haohui, et al.
Publicado: (2023)

Immune Evasion of SARS-CoV-2 Omicron Subvariants
por: Ke, Hanzhong, et al.
Publicado: (2022)

Molecular Evolutionary Analyses of the Spike Protein Gene and Spike Protein in the SARS-CoV-2 Omicron Subvariants
por: Nagasawa, Norika, et al.
Publicado: (2023)

Reinfections with Different SARS-CoV-2 Omicron Subvariants, France
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

Genomic architecture and evolutionary relationship of BA.2.75: A Centaurus subvariant of Omicron SARS-CoV-2
por: Basheer, Atia, et al.
Publicado: (2023)

The Rise of SARS-CoV-2 (COVID-19) Omicron Subvariant Pathogenicity
por: DeGrasse, David C, et al.
Publicado: (2023)

Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children
por: Li, Xiaohe, et al.
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants
por: Tamura, Tomokazu, et al.
Publicado: (2023)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75
por: Wang, Qian, et al.
Publicado: (2022)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
por: Dijokaite-Guraliuc, Aiste, et al.
Publicado: (2022)

Emergence of the Omicron SARS-CoV-2 subvariants during the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants
por: Moriyama, Miyu, et al.
Publicado: (2023)

Comparison of the replication and neutralization of different SARS‐CoV‐2 Omicron subvariants in vitro
por: Zhang, Yaqing, et al.
Publicado: (2023)

Correction: The Rise of SARS-CoV-2 (COVID-19) Omicron Subvariant Pathogenicity
por: DeGrasse, David C, et al.
Publicado: (2023)

Effects of tea, catechins and catechin derivatives on Omicron subvariants of SARS-CoV-2
por: Shin-Ya, Masaharu, et al.
Publicado: (2023)

Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
por: Chiang, Hsiao-Ling, et al.
Publicado: (2023)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
por: Ao, Danyi, et al.
Publicado: (2023)

Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
por: Kimura, Izumi, et al.
Publicado: (2022)

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
por: Wang, Xue-Jun, et al.
Publicado: (2022)

Genomic evidence for reinfection with different Omicron subvariants
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England
por: Strasser, Zachary H., et al.
Publicado: (2022)

Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants
por: Cho, Junhyung, et al.
Publicado: (2023)

SARS-CoV-2 Omicron subvariant spike N405 unlikely to rapidly deamidate
por: Beaudoin, Christopher A., et al.
Publicado: (2023)

XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant
por: Islam, Md. Aminul, et al.
Publicado: (2023)

Epidemiology and analysis of SARS-CoV-2 Omicron subvariants BA.1 and 2 in Taiwan
por: Liu, Li-Teh, et al.
Publicado: (2023)

SARS-CoV-2/Omicron subvariants: global outbreak upsurge and expected upcoming threats
por: Malik, Sumira, et al.
Publicado: (2023)

Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant
por: Karyakarte, Rajesh P, et al.
Publicado: (2023)

SARS-CoV-2 Omicron Subvariants Balance Host Cell Membrane, Receptor, and Antibody Docking via an Overlapping Target Site
por: Overduin, Michael, et al.
Publicado: (2023)

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity
por: Tang, Haijun, et al.
Publicado: (2021)

Detection of the Omicron BA.2.75 subvariant in Japan
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization
por: Morris, C. Paul, et al.
Publicado: (2022)

Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization
por: Morris, C Paul, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nsqqp00chivvfnrt5lb56ovhrb